• 1
    World Health Organization, ed. The global burden of disease: 2004 update—Annex A: Deaths and DALYs 2004 Annex tables. WHO, Geneva, 2008.
  • 2
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893917.
  • 3
    United Nations. World Population Prospects, the 2010 Revision. Accessed on 17 August, 2011.
  • 4
    Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991–2006. Int J Cancer 2010; 126: 118795.
  • 5
    United Nations General Assembly—Resolutions, 64th Session, 2010.
  • 6
    WHO. Cancer prevention and control: a Strategy for the WHO African Region. Yaounde, Republic of Cameroon: WHO, 2008. Report No.: AFR/RC58/9.
  • 7
    Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in Indigenous Africans—burden, distribution, and trends. Lancet Oncol 2008; 9: 68392.
  • 8
    Sitas F, Parkin DM, Chirenje M, Stein L, Abratt R, Wabinga H. Part II: Cancer in Indigenous Africans—causes and control. Lancet Oncol 2008; 9: 78695.
  • 9
    Ly A. Cancer et environment en Afrique. Oncologie 2007; 9: 3709.
  • 10
    Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 178999.
  • 11
    Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis 2010; 31: 7182.
  • 12
    Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El-Ghissassi F, Ibrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens—part B: biological agents. Lancet Oncol 2009; 10: 3212.
  • 13
    Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N, Liomba G, Batumba M, Lagos D, Gratrix F, Boshoff C, Casabonne D, et al. Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case–control study. PLoS One 2008; 3: e2505.
  • 14
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118: 303044.
  • 15
    Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, Law SC, Ahn YO, Xiang YB, Yeole BB, Shin HR, Shanta V, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol 2010; 11: 16573.
  • 16
    Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010; 376: 118693.
  • 17
    Union for International Cancer Control. UICC Special reports. 2010. com_content&task=view&id=16583. Accessed on 17 August, 2011.
  • 18
    Dye TD, Bogale S, Hobden C, Tilahun Y, Hechter V, Deressa T, Bize M, Reeler A. A mixed-method assessment of beliefs and practice around breast cancer in Ethiopia: implications for public health programming and cancer control. Global Public Health 2010; 22: 113.
  • 19
    Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M and Boyle P. Cancer incidence in five continents, vol. IX. Lyon, France: IARC Scientific Publications No. 160, 2008.
  • 20
    UICC Declaration. Accessed on 17 August, 2011.
  • 21
    Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 138594.
  • 22
    Denny L, Kuhn L, Hu CC, Tsai WY, Wright TCJr. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst 2010; 102: 155767.
  • 23
    Anon. Financing HPV vaccination in developing countries. Lancet 2011; 377: 1544.
  • 24
    Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 134855.
  • 25
    Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, Montesano R, Plymoth A, Sam O, Van der SM, Whittle H, Hainaut P. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 321623.
  • 26
    WHO/UNICEF coverage estimates 1980–2008. Accessed on 17 August, 2011.
  • 27
    Turner PC, Sylla A, Gong YY, Diallo MS, Sutcliffe AE, Hall AJ, Wild CP. Reduction in exposure to carcinogenic aflatoxins by postharvest intervention measures in West Africa: a community-based intervention study. Lancet 2005; 365: 19506.
  • 28
    van der Westhuizen L, Shephard GS, Burger HM, Rheeder JP, Gelderblom WC, Wild CP, Gong YY. Fumonisin B1 as a urinary biomarker of exposure in a maize intervention study among South African subsistence farmers. Cancer Epidemiol Biomarkers Prev 2011; 20: 4839.
  • 29
    Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19: 1419.
  • 30
    The Tobacco Atlas, 3rd edn. The American Cancer Society and World Lung Foundation, 2009. press_4–14-10.html. Accessed on 17 August, 2011.
  • 31
    World Cancer Report. Lyon, France: International Agency for Research on Cancer; 2008. Accessed on 17 August, 2011.
  • 32
    Ziraba AK, Fotso JC, Ochako R. Overweight and obesity in urban Africa: a problem of the rich or the poor? BMC Public Health 2009; 9: 465.
  • 33
    WHO global strategy on diet, physical activity and health. WHO, Geneva, 2004.
  • 34
    Gotch F, Gilmour J. Science, medicine and research in the developing world: a perspective. Nat Immunol 2007; 8: 12736.